Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-901-9 | CAS number: 7778-39-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- repeated dose toxicity: oral
- Remarks:
- combined repeated dose and carcinogenicity
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Study period:
- 1967
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, but test conditions and results not sufficiently detailed.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 967
Materials and methods
- Principles of method if other than guideline:
- Combined chronic toxicity/carcinogenicity studies
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Disodium hydrogenarsenate
- EC Number:
- 231-902-4
- EC Name:
- Disodium hydrogenarsenate
- Cas Number:
- 7778-43-0
- IUPAC Name:
- disodium hydrogen arsenate
- Details on test material:
- - Name of test material (as cited in study report): Sodium arsenate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Osborne-Mendel
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 2 years
- Frequency of treatment:
- Daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
400, 250, 125, 62.5 and 31.25 ppm
Basis:
nominal in diet
- No. of animals per sex per dose:
- 50 animals/sex/dose
- Control animals:
- yes, concurrent no treatment
Results and discussion
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 31.25 - 400 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Overall effects: Decreased survival, weight depression and enlargement of common bile duct
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
- Marked enlargement of the common bile duct in 25 and 42 animals at 250 and 400 ppm, respectively. These levels also caused weight depression and decreased survival.
- At 250 ppm, survival was slightly reduced, enlargement of the common bile duct (less pronounced) and reduced weight, particularly in females
- At 125, 62.5 and 31.25 ppm, arsenate did not cause common bile duct enlargement and did not affect survival. Body weight was slightly reduced in both sexes at 125 ppm
- No carcinogenic effect could be detected.
- Histopathologically, enlarged common bile ducts showed hyperplasia of the glandular elements, focal necrosis, and fibrosis.
Table 1: Weight and mortality of male and female rats fed sodium arsenate
Arsenic in dieta(ppm) |
Duration of experiment (weeks) |
Male |
Female |
||
Mean weight ± SE (g) |
Cumulative mortality |
Mean weight ± SE (g) |
Cumulative mortality |
||
Control |
12 |
409 .7 ± 9.31 |
0 |
238.5 ± 6.58 |
0 |
27 |
518.4 ± 10.86 |
0 |
292.7 ± 6.01 |
0 |
|
52 |
550 .0 ± 15.11 |
0 |
338.9 ± 8.01 |
1 |
|
78 |
580.4 ± 18.22 |
5 |
332.5 ± 13.46 |
4 |
|
104 |
489.0 ± 28.31 |
15 |
395.4 ± 24.40 |
17 |
|
31.25 |
12 |
411.2 ± 9.59 |
0 |
236.2 ± 4.18 |
0 |
27 |
528.5 ± 14.70 |
2 |
283.5 ± 6.95 |
0 |
|
52 |
557.8 ± 19.76 |
2 |
325.5 ± 8.72 |
1 |
|
78 |
562.1 ± 25.60 |
7 |
352.4 ± 12.26 |
6 |
|
104 |
440.7 ± 33.97 |
18 |
320.5 7 21.71 |
18 |
|
62.5 |
12 |
401.0 ± 7.56 |
0 |
230.5 ± 3.68 |
0 |
27 |
508.6 ± 9.66 |
0 |
286.8 ± 5.61 |
0 |
|
52 |
540 .5 ± 12.39 |
1 |
336.1 ± 7.85 |
0 |
|
78 |
574 .1 ± 16.15 |
4 |
365.0 ± 14.04 |
3 |
|
104 |
497.4 ± 28.50 |
14 |
345.8 ± 28.81 |
18 |
|
125 |
12 |
375.5 ± 6.00 |
0 |
228.7 ± 4.12 |
0 |
27 |
491.4 ± 9.24 |
0 |
258.4 ± 7.17 |
1 |
|
52 |
542.4 ± 18.19 |
5 |
313.6 ± 10.09 |
2 |
|
78 |
520.4 ± 36.67 |
7 |
321.8 ± 15.67 |
7 |
|
104 |
465.2 ± 26.90 |
15 |
310.6 ± 25.40 |
18 |
|
250 |
12 |
348.5 ± 6.09 |
0 |
205.4 ± 2.81 |
0 |
27 |
463.1 ± 10.25 |
1 |
250.0 ± 4.54 |
0 |
|
52 |
528.4 ± 16.18 |
3 |
285.0 ± 7.49 |
4 |
|
78 |
541.5 ± 23.27 |
10 |
285.9 ± 19.45 |
10 |
|
104 |
454.4 ± 27 .09 |
17 |
294.0 ± 63.51 |
20 |
|
400 |
12 |
245.0 ± 9.49 |
1 |
167.0 ± 4.84 |
1 |
27 |
305.8 ± 10.91 |
3 |
215.6 ± 4.77 |
1 |
|
52 |
420.9 ± 14.21 |
8 |
240.2 ± 7.71 |
5 |
|
78 |
443.9 ± 19.85 |
14 |
269.6 ± 8.98 |
8 |
|
104 |
414.6 ± 30.44 |
20 |
246.0 ± 13.62 |
21 |
a There were 25 animals in each group at the start
Applicant's summary and conclusion
- Conclusions:
- Under the test conditions, sodium arsenate had the effect on survival, weight depression and common bile duct enlargement in Osborne-Mendel rats.
- Executive summary:
In a 2 year study, sodium arsenate was administered through feed to groups of 50 weanling Osborne-Mendel rats/sex/dose at 400, 250, 125, 62.5 and 31.25 ppm. Mean starting body weight of male groups and female groups were 44 -46 g and 43 -45 g, respectively. Hematologic examinations were made on 10 males and 10 females from each group, after 3, 11, 17 and 22 months of the experiment. Body weights were recorded weekly. During 104th week of the feeding tests, animals from the appropriate groups were subjected to gross necropsy during which weights of heart, liver, spleen, kidney and testes were recorded. Histopathology was performed.
Slight increase of leukocyte count in the females at the highest dosage throughout the experiment and in the males for the first year. No distinct differences in ratio of organ weight to body weight were noted. Marked enlargement of the common bile duct was observed at 250 and 400 ppm and these levels also caused weight depression and decreased survival. At 250 ppm, survival was slightly reduced, enlargement of the common bile duct (less pronounced) and reduced weight, particularly in females was observed.At125, 62.5 and 31.25 ppm, arsenate did not cause common bile duct enlargement and did not affect survival. Body weight was slightly reduced in both sexes at 125 ppm. No carcinogenic effect could be detected. Histopathologically, enlarged common bile ducts showed hyperplasia of the glandular elements, focal necrosis and fibrosis.
Under the test conditions, sodium arsenate had the effect on survival, weight depression and common bile duct enlargement in Osborne-Mendel rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)